JP2016530291A5 - - Google Patents

Download PDF

Info

Publication number
JP2016530291A5
JP2016530291A5 JP2016539645A JP2016539645A JP2016530291A5 JP 2016530291 A5 JP2016530291 A5 JP 2016530291A5 JP 2016539645 A JP2016539645 A JP 2016539645A JP 2016539645 A JP2016539645 A JP 2016539645A JP 2016530291 A5 JP2016530291 A5 JP 2016530291A5
Authority
JP
Japan
Prior art keywords
metadoxine
composition
sustained release
disorder
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016539645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016530291A (ja
Filing date
Publication date
Priority claimed from US14/038,258 external-priority patent/US20150073023A1/en
Application filed filed Critical
Priority claimed from PCT/IB2014/002398 external-priority patent/WO2015033224A2/en
Publication of JP2016530291A publication Critical patent/JP2016530291A/ja
Publication of JP2016530291A5 publication Critical patent/JP2016530291A5/ja
Pending legal-status Critical Current

Links

JP2016539645A 2013-09-09 2014-09-09 脆弱x症候群および関連障害の処置方法 Pending JP2016530291A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361875384P 2013-09-09 2013-09-09
US61/875,384 2013-09-09
US14/038,258 2013-09-26
US14/038,258 US20150073023A1 (en) 2013-09-09 2013-09-26 Method Of Treating Fragile X Syndrome And Related Disorders
US201461991351P 2014-05-09 2014-05-09
US61/991,351 2014-05-09
PCT/IB2014/002398 WO2015033224A2 (en) 2013-09-09 2014-09-09 Methods of treating fragile x syndrome and related disorders

Publications (2)

Publication Number Publication Date
JP2016530291A JP2016530291A (ja) 2016-09-29
JP2016530291A5 true JP2016530291A5 (enExample) 2017-10-19

Family

ID=52629036

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016540930A Pending JP2016530536A (ja) 2013-09-09 2014-09-09 療法に対する奏効性の決定方法
JP2016539645A Pending JP2016530291A (ja) 2013-09-09 2014-09-09 脆弱x症候群および関連障害の処置方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016540930A Pending JP2016530536A (ja) 2013-09-09 2014-09-09 療法に対する奏効性の決定方法

Country Status (12)

Country Link
EP (2) EP3043792A2 (enExample)
JP (2) JP2016530536A (enExample)
KR (2) KR20160078956A (enExample)
CN (2) CN105917225A (enExample)
AU (2) AU2014315026A1 (enExample)
CA (2) CA2923421A1 (enExample)
EA (2) EA201690557A1 (enExample)
IL (2) IL244343A0 (enExample)
MX (2) MX2016003006A (enExample)
SG (2) SG11201601605YA (enExample)
TW (2) TW201606304A (enExample)
WO (2) WO2015035402A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6486353B2 (ja) * 2013-07-31 2019-03-20 ユー・ディー・シー アイルランド リミテッド 発光性ジアザベンゾイミダゾールカルベン金属錯体
US20150073023A1 (en) 2013-09-09 2015-03-12 Alcobra Ltd. Method Of Treating Fragile X Syndrome And Related Disorders
CN108538365A (zh) * 2017-03-24 2018-09-14 华东师范大学 一种基于数据分析技术的自闭症社交能力评估系统
US10864182B2 (en) * 2018-04-13 2020-12-15 Healx Limited Treatment of fragile X syndrome
KR20190121569A (ko) * 2018-04-18 2019-10-28 건국대학교 글로컬산학협력단 아그마틴 및 이의 약학적으로 허용 가능한 염을 포함하는 취약 x 증후군 예방 또는 치료용 약학조성물
CN112770739B (zh) * 2018-06-07 2023-12-12 奥维德医疗公司 (s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸及相关化合物在治疗发育障碍中的用途
KR102528677B1 (ko) * 2020-01-08 2023-05-04 주식회사 뉴로벤티 리수리드 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물
CN119139297A (zh) 2020-02-07 2024-12-17 株式会社纽若梵提 包含利美尼定的组合物的应用
KR20230031317A (ko) * 2020-06-29 2023-03-07 지네르바 파마슈티컬스, 인코포레이티드 칸나비디올로의 취약 x 증후군의 치료

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1131856B (it) 1980-06-30 1986-06-25 Baldacci Lab Spa Composizione farmaceutica per il trattamento di intossicazioni alcooliche
WO2002043507A2 (en) * 2000-11-30 2002-06-06 The Health Research Institute Nutrient supplements and methods for treating autism and for preventing the onset of autism
IL187159A0 (en) 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
EA023758B1 (ru) * 2009-06-25 2016-07-29 Алкобра Лтд. Применение метадоксина для лечения синдрома дефицита внимания/гиперактивности (adhd/add)

Similar Documents

Publication Publication Date Title
JP2016530291A5 (enExample)
HRP20210819T1 (hr) Fenfluramin za uporabu u liječenju dravet sindroma
JP2012193216A5 (enExample)
JP2018193377A5 (enExample)
JP2010248252A5 (enExample)
MY181159A (en) Sublingual and buccal film compositions
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
JP2014111603A5 (enExample)
JP2015515475A5 (enExample)
JP2015517488A5 (enExample)
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
JP2013505205A5 (enExample)
BR112015018168A2 (pt) inibidores de rock suaves
JP2016147915A5 (enExample)
JP2013231087A5 (enExample)
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
JP2015525757A5 (enExample)
MX2013003635A (es) Compuestos de n-heteroarilo.
ECSP12011703A (es) Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos
JP2013541583A5 (enExample)
PH12012502083A1 (en) Manufacturing of active-free granules and tablets comprising the same
AR091351A1 (es) Formulaciones de bromocriptina, metodo para mejorar el control glucemico y metodo para la fabricacion
BR112014014795A2 (pt) sistema de pélete de multiunidade de liberação imediata
JP2012516348A5 (enExample)
BR112014009580A2 (pt) composição farmacêutica de omeprazol